PANNEX Therapeutics is pioneering the development of Panx1 blockers, a new class of cancer drugs that block multiple pathways to stop growth, spread and survival of cancer cells. Pannex Therapeutics Inc. is an early-stage biopharmaceutical company founded to discover and develop novel therapies to transform cancer therapy based on blocking Pannexin1 channels (Panx1). This new class of drugs is based on the discovery that Pannexin 1 channels play a critically important role in the pathophysiology of many types of cancer. We are the first to translate this new pharmacological target into a new therapeutic approach for many types of cancer with high unmet medical need. We have developed a discovery platform to create unique, first-in-class Panx1 blockers. Our patent-protected, small molecule Panx1 blockers demonstrate high specificity for cancer cells and good safety profiles in preclinical models.